As Trump and RFK Jr. move to upend drug making, Seattle biotech bets on science
Robert F. Kennedy Jr. may soon be America's top pharmaceutical regulator. That is cause for concern in Seattle’s biotech ...
American Association of Individual Investors1d
Why Zentalis Pharmaceuticals, Inc.’s (ZNTL) Stock Is Down 21.25%
Zentalis Pharmaceuticals, Inc.’s ZNTL share price has dipped by 21.25%, which has investors questioning if this is right time ...
MSD and Eisai’s LEAP gastroesophageal cancer trial sees mixed success
MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but ...
appliedclinicaltrialsonline6d
Phase III LEAP-015 Trial Shows Mixed Results for Keytruda-Lenvima Combo in Advanced HER2-Negative Gastroesophageal Cancer
Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve ...
BioSpace6d
Merck’s Keytruda Combo Fails to Extend Survival in Phase III GI Cancer
The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...
Merck, Eisai See Mixed Keytruda/Lenvima Results in Phase 3 Gastroesophageal Cancer Study
Merck & Co. and Eisai reported mixed results from a late-stage study of the cancer drugs Keytruda and Lenvima in patients with certain types of gastroesophageal cancer.
Merck, Eisai's combination drug fails in late-stage trial for esophageal cancer
Merck and Eisai said on Friday a combination of their cancer therapies failed to extend the lives of patients with a type of ...